LHX2 dysregulations have been detected in several cancers; the DNA methylation of LHX2 provided the potential value by serving as a novel biomarker in cervical cancer radiotherapy [13], but the role of LHX2 in ESCC remains ambiguous. This evidence concerns the gene LHX2 and cervical carcinoma.